Harris, S I <br/><br/>
Upper gastrointestinal safety evaluation of parecoxib sodium, a new parenteral cyclooxygenase-2-specific inhibitor, compared with ketorolac, naproxen, and placebo.  [electronic resource] 

 -  Clinical therapeutics  Sep 2001 
 - 1422-8 p.  digital 
<br/><br/> Publication Type: Clinical Trial; Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>0149-2918 
<br/><br/><label>Standard No.: </label>10.1016/s0149-2918(01)80117-x  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Aged<br/>Analgesics, Non-Narcotic--adverse effects<br/>Anti-Inflammatory Agents, Non-Steroidal--adverse effects<br/>Cyclooxygenase 2<br/>Cyclooxygenase 2 Inhibitors<br/>Cyclooxygenase Inhibitors--adverse effects<br/>Double-Blind Method<br/>Female<br/>Gastric Mucosa--drug effects<br/>Humans<br/>Infusions, Parenteral<br/>Isoenzymes<br/>Isoxazoles--adverse effects<br/>Ketorolac--adverse effects<br/>Male<br/>Membrane Proteins<br/>Naproxen--adverse effects<br/>Peptic Ulcer--chemically induced<br/>Prostaglandin-Endoperoxide Synthases